All in the Genes
By Marcy Darnovsky and Hank Greely,
Democracy
| 08. 31. 2008
Henry Greely inaccurately characterizes my organization, the Center for Genetics and Society, as "drawn to arguments against [inheritable human genetic enhancement] by the lure of naturalness" ["The Genetics of Fear," Issue #9].
I am not sure how Greely reached this conclusion. We explicitly ground our opposition in our commitments to social justice and equality. Procedures that produce (or claim to produce) genetically superior children for those with access to expensive technologies would all too likely exacerbate inequalities and lead to new forms of discrimination.
Greely seems enthusiastic about inheritable genetic modification, but he also recognizes that significant improvements are a long way off. He therefore dismisses proposals, such as the one offered by Jamie Metzl, for international agreements to prohibit socially undesirable human biotechnologies ["Brave New World War," Issue #8]. He disparages efforts at international regulation as "neither progressive nor wise," without mentioning that similar regulations are already in effect, and working well, in over four dozen countries. The United States should join this growing international consensus.
Greely warns ominously that regulating biotechnology "would almost certainly...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...
By Staff, The Medicine Maker | 03.21.2025
"The Promise and Peril of CRISPR" cover by Johns Hopkins University Press
As a paediatrician taking care of children with sickle cell disease, Neal Baer, a Harvard Medical School graduate, was in awe of the power of CRISPR technologies. Later...